Hematopoietic diseases

Substitute preparations for blood coagulation disorders (hemophilia, TTP, antidote, paroxysmal nocturnal hemoglobinuria (PNH)) belong to this category. To date, the G-BA has assessed 36 such products in 54 procedures. In the 62 observed subpopulations, 0% have seen a major, 2.9% a considerable and 7% a minor additional benefit in relation to the comparative therapy. A non-quantifiable additional benefit has been proved for 32.4% of the subpopulations.

By contrast, no additional benefit has been proved for 57.9% of the subpopulations weighted by patient share per resolution. In total, this includes 95% of the 0.34 million patients relevant for treatment with the assessed medicinal products.